Pediatric systemic lupus erythematosus. Retrospective analysis of clinico-laboratory parameters and their association with Systemic Lupus Erythematosus Disease Activity Index score

被引:8
|
作者
Nazri, Siti Khadijah S. M. [1 ]
Wong, Kah K. [1 ]
Hamid, Wan Zuraida W. A. [1 ]
机构
[1] Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Hlth Campus, Kelantan, Malaysia
关键词
GLOMERULONEPHRITIS; CLASSIFICATION; MANIFESTATIONS;
D O I
10.15537/smj.2018.6.22112
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To elucidate the clinico-laboratory characteristics associated with pediatric systemic lupus erythematosus (pSLE) patients with higher Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score in a retrospective cohort of pSLE patients. Methods: A retrospective study involving 32 pSLE patients was conducted at Hospital Universiti Sains Malaysia, Kelantan, Malaysia between 2006 and 2017. Results: Within the group of 32 pSLE patients, 23 were girls and 9 were boys (3: 1 ratio). The most common symptom was renal disorder (n = 21; 65.6%) followed by malar rash (n = 9; 28.1%), oral ulcers (n = 7; 21.9%), prolonged fever (n = 5; 15.6%) and arthritis (n = 4; 12.5%). Antinuclear antibodies (ANA) were detected in all patients and 25 patients (78.1%) were positive for anti-double stranded DNA (anti-dsDNA) antibodies. Eighteen (56.3%) patients had active SLE (SLEDAI = 6), and these patients were significantly associated with heavy pyuria (p = 0.004), a high ANA concentration (1: 160; p = 0.040, 1: 320; p = 0.006), elevated ESR (p = 0.006), low C3 levels (p = 0.008), oral ulcers (p = 0.010), heavy hematuria (p = 0.017) and heavy proteinuria (p = 0.017), lupus erythematosus (LE)-nonspecific lesion manifestations (p = 0.019) and malar rash (p = 0.044). Conclusion: Pediatric systemic lupus erythematosus patients with higher SLEDAI score were most significantly associated with pyuria, high ANA titers, and elevated ESR.
引用
收藏
页码:627 / 631
页数:5
相关论文
共 50 条
  • [41] Late onset systemic lupus erythematosus.
    Boddaert, J
    Huong, DLT
    Amoura, Z
    Wechsler, B
    Godeau, P
    Piette, JC
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S583 - S583
  • [42] Prolidase deficiency in systemic lupus erythematosus.
    D'souza, Anil
    Kurien, Biji T.
    Patel, Nisha C.
    Miller, David L.
    Wang, Heng
    Scofield, R. Hal
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S292 - S292
  • [43] Epileptic seizures in systemic lupus erythematosus.
    Appenzeller, S
    Cendes, F
    Costallat, LTL
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S182 - S182
  • [44] Clinical trials in systemic lupus erythematosus.
    Buyon J.P.
    Current Rheumatology Reports, 2000, 2 (1) : 11 - 12
  • [45] Response to aspirin in systemic lupus erythematosus.
    Avalos, I
    Chung, CP
    Oeser, A
    Morrow, JD
    Stein, CM
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S602 - S603
  • [46] Tuberculosis in patients with systemic lupus erythematosus.
    Kim, CH
    Do, JH
    Ko, HJ
    Jung, YO
    Min, DJ
    Kim, WU
    Lee, SH
    Cho, CS
    Kim, HY
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S60 - S60
  • [47] Mycophenolate mofetil for systemic lupus erythematosus.
    Pashinian, N
    Wallace, DJ
    Klinenberg, JR
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S110 - S110
  • [48] Predictors of survival in systemic lupus erythematosus.
    Kasitanon, N
    Magder, L
    Petri, M
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S186 - S186
  • [49] Immunosuppressive treatment of systemic lupus erythematosus.
    Euler, HH
    Schroeder, JO
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1995, 24 (12) : 686 - 696
  • [50] Metabolic Underpinnings of Systemic Lupus Erythematosus.
    Wu, Tianfu
    Xie, Chun
    Han, Jie
    Blanco, Irene
    Olsen, Nancy J.
    Putterman, Chaim
    Saxena, Ramesh
    Mohan, Chandra
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S560 - S560